Compositions and methods for treatment of thyroid eye disease

Abstract

Antibodies and compositions against IGF-1R and uses thereof are provided herein.

1 .- 47 . (canceled) 
     
     
         48 . A method of treating thyroid eye disease by inhibiting insulin-like growth factor I receptor (IGF-IR) activity in a subject in need thereof, the method comprising:
 administering a first dose of a pharmaceutical composition comprising an antibody at a dose of 10 mg/kg to the subject in need thereof;   administering a second dose of the pharmaceutical composition comprising the antibody at a dose of 10 mg/kg to the subject 3 weeks after the first dose; and   administering three or more subsequent doses of the pharmaceutical composition comprising the antibody at a dose of 10 mg/kg to the subject every 3 weeks,   wherein the antibody comprises a light chain variable region having the amino acid sequence of SEQ ID NO: 13 and a heavy chain variable region having the amino acid sequence of SEQ ID NO: 14.   
     
     
         49 . The method of  claim 48 , wherein the subject is administered the pharmaceutical composition for a total of 5 doses to about 8 doses. 
     
     
         50 . The method of  claim 49 , wherein the subject is administered the pharmaceutical composition for a total of 5 doses. 
     
     
         51 . The method of  claim 49 , wherein the subject is administered the pharmaceutical composition for a total of 8 doses. 
     
     
         52 . The method of  claim 48 , wherein the antibody comprises a light chain having the amino acid sequence of SEQ ID NO: 93 and a heavy chain having the amino acid sequence of SEQ ID NO: 92. 
     
     
         53 . The method of  claim 49 , wherein the antibody comprises a light chain having the amino acid sequence of SEQ ID NO: 93 and a heavy chain having the amino acid sequence of SEQ ID NO: 92. 
     
     
         54 . The method of  claim 50 , wherein the antibody comprises a light chain having the amino acid sequence of SEQ ID NO: 93 and a heavy chain having the amino acid sequence of SEQ ID NO: 92. 
     
     
         55 . The method of  claim 51 , wherein the antibody comprises a light chain having the amino acid sequence of SEQ ID NO: 93 and a heavy chain having the amino acid sequence of SEQ ID NO: 92. 
     
     
         56 . The method of  claim 48 , wherein the pharmaceutical composition is administered intravenously or subcutaneously. 
     
     
         57 . The method of  claim 56 , wherein the pharmaceutical composition is administered intravenously. 
     
     
         58 . The method of  claim 56 , wherein the pharmaceutical composition is administered subcutaneously. 
     
     
         59 . The method of  claim 48 , wherein treating the thyroid eye disease reduces proptosis in an eye in the subject. 
     
     
         60 . The method of  claim 49 , wherein treating the thyroid eye disease reduces proptosis in an eye in the subject. 
     
     
         61 . The method of  claim 50 , wherein treating the thyroid eye disease reduces proptosis in an eye in the subject. 
     
     
         62 . The method of  claim 51 , wherein treating the thyroid eye disease reduces proptosis in an eye in the subject. 
     
     
         63 . The method of  claim 59 , wherein proptosis is reduced by at least 2 mm. 
     
     
         64 . The method of  claim 48 , wherein treating the thyroid eye disease reduces clinical activity score (CAS) in the subject. 
     
     
         65 . The method of  claim 48 , wherein treating the thyroid eye disease reduces proptosis by at least 2 mm and reduces clinical activity score (CAS) of the subject. 
     
     
         66 . The method of  claim 48 , wherein treating the thyroid eye disease improves or reduces the severity of diplopia in the subject. 
     
     
         67 . The method of  claim 66 , wherein the diplopia is constant diplopia, inconstant diplopia, or intermittent diplopia.